A bibliometric analysis reveals a significant rise in AI applications in immune checkpoint inhibitor research, particularly in predicting treatment responses and managing adverse events.

July 31, 2026Read signal →

Competitive LandscapeCMP

oncology portfolio teams

Focal Asset

Bruceine

Focal Asset

Bruceine

Indication

Oncology / Lung Adenocarcinoma

Signal Score

8.2

Competitivehigh signal

Bruceine D shows potential to overcome EGFR-TKI resistance in lung adenocarcinoma

Bruceine D epigenetically restores SMAD3 expression and suppresses malignant progression in EGFR-TKI-resistant lung adenocarcinoma.

July 24, 2026Read signal →

Competitive LandscapeCMP

Focal Asset

Lead Asset

Focal Asset

Lead Asset

Indication

Memorial Sloan Kettering Cancer Center

Signal Score

8.2

Competitivehigh signal

CAR-T Cell Therapy for ALL: Emerging Research Trends and Focus Areas Identified

A bibliometric analysis reveals a significant growth in CAR-T cell therapy research for acute lymphoblastic leukemia, with a focus on long-term outcomes and risk assessment.

July 22, 2026Read signal →

Competitive LandscapeCMP

Focal Asset

Infrastructure

Focal Asset

Infrastructure

Indication

H. Lee Moffitt Cancer Center

Signal Score

8.2

Competitivehigh signal

Infrastructure Proposal for mHealth Interventions in Cancer Patient Smoking Cessation

A new infrastructure is being proposed to support the development of mobile health tools aimed at reducing smoking among cancer patients.

July 18, 2026Read signal →

Competitive LandscapeCMP

ANDA218552

Focal Asset

APOTEX

Focal Asset

APOTEX

Indication

Not specified

Signal Score

6.8

Competitivemoderate signal

FDA Submission Update for ANDA218552 by APOTEX

APOTEX has submitted ANDA218552 with a standard review priority.

July 16, 2026Read signal →

Competitive LandscapeCMP

Focal Asset

FDA

Focal Asset

FDA

Indication

Mental Health / Psychedelics

Signal Score

8.4

Competitivehigh signal

FDA Supports Development of Psychedelic Drugs for Mental Health

The FDA is actively supporting the development of psychedelic drugs aimed at treating serious mental health conditions.

July 14, 2026Read signal →

Competitive LandscapeCMP

Drug	MOA / Company	Stage
Lead Asset	Roche	Lead

Focal Asset

Lead Asset

Company

Roche

Indication

Infectious Diseases / Hepatitis D

Signal Score

8.4

Competitivehigh signal

Roche Launches First Fully Automated HDV Test to Enhance Diagnosis and Monitoring

Roche has introduced the cobas HDV test, the first fully automated diagnostic solution for Hepatitis D Virus, enhancing diagnosis and treatment monitoring.

July 14, 2026Read signal →

Competitive LandscapeCMP

Focal Asset

Novel

Focal Asset

Novel

Indication

HCT116 colorectal cancer models

Signal Score

8.4

Competitivehigh signal

Novel CDK7 Inhibitor 7a Shows Potent Antitumor Activity in Colorectal Cancer Models

Compound 7a is a highly selective CDK7 inhibitor with an IC50 of 1.9 nM, demonstrating significant antitumor efficacy in HCT116 models.

July 14, 2026Read signal →

Competitive LandscapeCMP

NSP13 inhibitors

COVID-19 treatments

Focal Asset

Advances

antiviral developers

Focal Asset

Advances

Indication

Infectious Disease / Coronavirus

Signal Score

8.4

Competitivehigh signal

Advances in NSP13 helicase inhibitors for broad-spectrum anti-coronavirus therapy

NSP13 helicase is a promising target for broad-spectrum anti-coronavirus drugs, with recent progress in inhibitor development.

July 9, 2026Read signal →

Competitive LandscapeCMP

Focal Asset

cetuximab

Focal Asset

cetuximab

Indication

cancer patients with EGFR resistance

Signal Score

8.4

Competitivehigh signal

Novel bispecific T-cell engagers show promise against EGFR resistance in cancer

New bispecific T-cell engagers targeting EGFR escape variants show effective T cell-mediated cytotoxicity.

July 7, 2026Read signal →

Competitive LandscapeCMP

Drug	MOA / Company	Stage
Lead Asset	Roche	Lead

Focal Asset

Lead Asset

Company

Roche

Indication

Oncology / Genomics

Signal Score

8.4

Competitivehigh signal

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform

Roche has launched the AXELIOS 1 platform, a next-generation sequencing solution that offers high accuracy, speed, and cost efficiency.

June 29, 2026Read signal →

Competitive LandscapeCMP

Drug	MOA / Company	Stage
Lead Asset	Roche	Lead

Focal Asset

Lead Asset

Company

Roche

Indication

Genomics / Sequencing Technology

Signal Score

8.4

Competitivehigh signal

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform

Roche has launched AXELIOS 1, a next-generation sequencing platform utilizing innovative SBX technology for rapid and accurate whole-genome sequencing.

June 29, 2026Read signal →

Competitive LandscapeCMP

Drug	MOA / Company	Stage
mRNA-LNP	pharma companies in infectious diseases	Lead
TP0435 mRNA-LNP vaccine	—	Competing

Focal Asset

mRNA-LNP

Company

pharma companies in infectious diseases

Indication

Infectious Disease / Syphilis

Signal Score

8.4

Competitivehigh signal

mRNA-LNP Vaccine TP0435 Shows Promise Against Syphilis in Animal Models

The TP0435 mRNA-LNP vaccine demonstrated strong protective immunity against Treponema pallidum in rabbits, outperforming protein vaccines.

June 24, 2026Read signal →

Competitive LandscapeCMP

synthetic biology firms

Focal Asset

Advances

Focal Asset

Advances

Indication

bacteria-based cancer therapies

Signal Score

8.2

Competitivehigh signal

Advances in Bacteria-Based Cancer Immunotherapy via Synthetic Biology

Synthetic biology techniques are enhancing the efficacy of bacteria-based cancer immunotherapies by improving tumor targeting and immune activation.

June 22, 2026Read signal →

Competitive LandscapeCMP

Focal Asset

Emerging

Focal Asset

Emerging

Indication

Oncology / CAR-T

Signal Score

8.2

Competitivehigh signal

Emerging Trends in CAR-T Immunotherapy Research for Breast Cancer Identified

A bibliometric analysis reveals significant research activity in CAR-T immunotherapy for breast cancer, highlighting key contributors and emerging hotspots.

June 21, 2026Read signal →

Competitive LandscapeCMP

Drug	MOA / Company	Stage
Ophthalmology	Novartis	Lead

Focal Asset

Ophthalmology

Company

Novartis

Indication

Ophthalmology / Ocular Inflammation

Signal Score

8.4

Competitivehigh signal

Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

The Pra-ffd hydrogel demonstrated improved bioavailability and reduced ocular inflammation in preclinical models.

June 17, 2026Read signal →

Competitive LandscapeCMP

Drug	MOA / Company	Stage
Hyperlipidemia	Merck	Lead
Cardiovascular	—	Competing

Focal Asset

Hyperlipidemia

Company

Merck

Indication

Cardiovascular / PCSK9 Inhibition

Signal Score

8.4

Competitivehigh signal

Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate

Merck has published a method for the large-scale synthesis of enlicitide decanoate, an investigational oral PCSK9 inhibitor.

June 16, 2026Read signal →

Competitive LandscapeCMP

Drug	MOA / Company	Stage
Hepatology	Roche	Lead

Focal Asset

Hepatology

Company

Roche

Indication

Hepatocellular Carcinoma

Signal Score

8.4

Competitivehigh signal

Roche Launches Liver Disease Panel to Enhance Chronic Liver Disease Management

Roche has launched the Liver Disease Panel, a suite of certified algorithms aimed at improving the management of chronic liver disease (CLD). This panel includes the LiverPRO algorithm, which facilitates early detection of liver fibrosis using routine blood markers.

June 16, 2026Read signal →

Competitive Signals

MammoVerse Study to Enhance Emotional Support for Breast Cancer Patients

AI Transforming Immune Checkpoint Inhibitor Research: Key Trends Identified

Bruceine D shows potential to overcome EGFR-TKI resistance in lung adenocarcinoma

CAR-T Cell Therapy for ALL: Emerging Research Trends and Focus Areas Identified

Infrastructure Proposal for mHealth Interventions in Cancer Patient Smoking Cessation

FDA Submission Update for ANDA218552 by APOTEX

FDA Supports Development of Psychedelic Drugs for Mental Health

Roche Launches First Fully Automated HDV Test to Enhance Diagnosis and Monitoring

Novel CDK7 Inhibitor 7a Shows Potent Antitumor Activity in Colorectal Cancer Models

Advances in NSP13 helicase inhibitors for broad-spectrum anti-coronavirus therapy

Novel bispecific T-cell engagers show promise against EGFR resistance in cancer

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform

mRNA-LNP Vaccine TP0435 Shows Promise Against Syphilis in Animal Models

Advances in Bacteria-Based Cancer Immunotherapy via Synthetic Biology

Emerging Trends in CAR-T Immunotherapy Research for Breast Cancer Identified

Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate

Roche Launches Liver Disease Panel to Enhance Chronic Liver Disease Management

Get signals before the market moves

Competitive Signals

MammoVerse Study to Enhance Emotional Support for Breast Cancer Patients

AI Transforming Immune Checkpoint Inhibitor Research: Key Trends Identified

Bruceine D shows potential to overcome EGFR-TKI resistance in lung adenocarcinoma

CAR-T Cell Therapy for ALL: Emerging Research Trends and Focus Areas Identified

Infrastructure Proposal for mHealth Interventions in Cancer Patient Smoking Cessation

FDA Submission Update for ANDA218552 by APOTEX

FDA Supports Development of Psychedelic Drugs for Mental Health

Roche Launches First Fully Automated HDV Test to Enhance Diagnosis and Monitoring

Novel CDK7 Inhibitor 7a Shows Potent Antitumor Activity in Colorectal Cancer Models

Advances in NSP13 helicase inhibitors for broad-spectrum anti-coronavirus therapy

Novel bispecific T-cell engagers show promise against EGFR resistance in cancer

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform

mRNA-LNP Vaccine TP0435 Shows Promise Against Syphilis in Animal Models

Advances in Bacteria-Based Cancer Immunotherapy via Synthetic Biology

Emerging Trends in CAR-T Immunotherapy Research for Breast Cancer Identified

Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate

Roche Launches Liver Disease Panel to Enhance Chronic Liver Disease Management

Get signals before the market moves